Table 4.

Morphokinetic timings (hours) of embryos from patients treated with GnRH agonists or GnRH antagonists.

	GnRH agonist			GnRH antagonist
	Mean±Std.Dev. (hours)	CI 95% (hours)	n	Mean ± Std.Dev. (hours)	CI 95% (hours)	n	p*
t2-tPNf	3.1 ± 2.9	2.7–3.6	167	2.7 ± 0.6	2.6–2.8	152	0.30
t3-tPNf	14.7 ± 4.9	13.9–15.5	161	14.9 ± 4.4	14.1–15.6	145	0.38
t4-tPNf	17.8 ± 7.8	16.5–19.0	156	16.7 ± 6.4	15.7–17.8	138	0.70
t5-tPNf	29.8 ± 8.7	28.4–31.2	147	30.9 ± 10.6	29.1–32.8	126	0.38
t6-tPNf	30.9 ± 8.4	29.5–32.3	137	31.6 ± 8.3	30.0–33.1	118	0.37
t7-tPNf	33.7 ± 9.3	32.1–35.3	132	33.8 ± 9.9	32.0–35.6	115	0.91
t8-tPNf	35.1 ± 9.3	33.4–36.8	119	35.4 ± 10.3	33.4–37.4	106	0.91
t9+ -tPNf	48.9 ± 8.0	47.3–50.4	102	50.3 ± 7.9	48.7–51.9	92	0.35
tM-tPNf	64.5 ± 8.4	62.7–66.3	88	66.7 ± 9.5	64.6–68.9	80	0.39
tSB-tPNf	73.0 ± 6.4	71.4–74.6	62	74.8 ± 6.8	73.0–76.6	59	0.18
tB-tPNf	78.9 ± 6.7	77.0–80.8	49	81.2 ± 5.0	79.7–82.7	45	0.08
tEB-tPNf	81.3 ± 6.0	79.2–83.3	36	83.2 ± 4.5	81.6–84.9	32	0.24
ECC1 (=t2-tPB2)	24.6 ± 4.7	23.8–25.4	129	24.2 ± 3.7	23.4–25.0	91	0.66
ECC2 (=t4-t2)	14.8 ± 7.5	13.6–16.0	158	13.9 ± 6.2	12.9–15.0	145	0.65
ECC3 (=t8-t4)	19.7 ± 7.8	18.3–21.1	121	19.9 ± 9.2	18.2–21.6	113	0.72
s2 (=t4-t3)	3.2 ± 6.1	2.2–4.1	158	2.5 ± 5.7	1.6–3.4	145	0.24
s3 (=t8-t5)	7.6 ± 7.3	6.3–8.9	121	6.7 ± 7.9	5.2–8.2	113	0.09

Presented are the mean, standard deviation (std. dev.) and the 95% confidence interval (CI).

^*Mann-Whitney U Asymp. Sig. (2-tailed).